A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosis (PBC)
- Conditions
- primary biliary cirrhosisliver cirrhosis1001965410003816
- Registration Number
- NL-OMON41920
- Lead Sponsor
- Fast Forward Pharmaceuticals B.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 8
1) Willing and able to provide signed written informed consent to participate in the study.
2) Willing and able to comply with all study procedures and scheduled visits.
3) Male or Female Age between 18 and 75 years of age inclusive at the time of signing the informed consent.
4) Established diagnosis of PBC according to the EASL criteria (European Association for the Study of the Liver 2009): A diagnosis of PBC can be made with confidence in adult patients with otherwise unexplained elevation of ALP and presence of AMA (>=1:40), and/or AMA type M2. A liver biopsy is not essential for the diagnosis of PBC in these patients, but allows activity and stage of the disease to be assessed.
5) Having a screening ALP serum level between 1.67 and 5 x ULN inclusive.
6) Be on a stable dose of UDCA 12-20 mg/kg/day for at least 3 months prior to screening or intolerant of UDCA in the opinion of the investigator (no UDCA for at least 8 weeks prior to screening).
7) Are not pregnant or breast feeding and do not plan to become pregnant or father a child during the study. Female subjects (of childbearing potential) must be willing to use two medically accepted forms of contraception throughout the study and must be willing to submit to pregnancy test(s). Male subjects must agree to use medically accepted contraception methods with their partners throughout the study as described above, unless they have had a prior vasectomy.
8) Has the ability to communicate adequately with the study staff and to comply with the requirements of the entire study, with the help of a caregiver, if applicable.
1) Laboratory screening results
a) ALT >5x ULN
b) AST >5x ULN
c) Total bilirubin >2x ULN. Isolated bilirubin >2xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%
d) Total WBC <3000 cells/mm3
e) Absolute neutrophil count (ANC) <1500 cells/mm3
f) Platelet count <100,000/mm3
g) Prothrombin time (international normalized ratio (INR) >1.2
2) BMI >=35 or suspected to have relevant nonalcoholic fatty liver disease (NAFLD) as based on the judgment of the Investigator at screening
3) Subject has a history of, or current viral hepatitis B or C (including hepatitis B surface antigen [HBsAg], hepatitis B core antibody and hepatitis C virus antibody [anti-HCV] positivity), or a positive HIV antibody screen at time of screening
4) Recipients of liver or other organ transplantation or anticipated need for orthotropic organ transplantation in one year as determined by the Mayo Risk Score
5) Co-existing liver or biliary diseases, such as primary sclerosing cholangitis, choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), cholangiocarcinoma diagnosed or suspected liver cancers
6) Recurrent variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class B/C, Esophageal Varices, or refractory ascites within the previous 6 months of screening (defined as date informed consent signed)
7) Have a family history (more than one first degree relative) of multiple thrombotic events or a personal history of any venous or arterial thrombotic event including deep vein thrombosis, stroke, myocardial infarction, pulmonary embolus, or peripheral arterial thromboembolic events
8) Prohibited medications 6 months prior to screening: azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide and other systemic corticosteroids; potentially hepatotoxic drugs (including a-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin)
9) Prohibited medications 12 months prior to screening: antibodies or immunotherapy directed against interleukins or other cytokines or chemokines
10) Subjects with recurrent bacterial infections (as judged by the investigator) within 6 months prior to screening, active bacterial, fungal or mycobacterial infections observed during screening, or any recent episode of infection requiring hospitalizations or treatment with antibiotics (within the 3 months prior to screening)
11) History of malignancy, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
12) Immunization with a live vaccine within 4 weeks of Screening, with the exception of influenza vaccine and no planned immunizations within the period of the study.
13) Known clinically significant cardiac disease (e.g., myocardial infarction or stroke, unstable angina, claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG) abnormality within the previous 12 months prior to screening.
14) Subjects with evidence of other serious, significant, acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to comple
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>This is an exploratory study to evaluate the safety and tolerability,<br /><br>pharmacokinetics and efficacy of FFP104. The general strategy of the<br /><br>analysis will be to examine the data summaries for any trends amongst the dose<br /><br>levels. No formal hypothesis testing will be conducted.<br /><br>Exploratory comparisons between dose cohorts can be performed, using<br /><br>non-parametrical statistical methods.</p><br>
- Secondary Outcome Measures
Name Time Method